Precise coding and payer follow-through for diabetes, thyroid, bone health, and pituitary care, so claims clear on the first pass and fewer dollars sit unpaid.
Supporting endocrinology and diabetes care practices across the United States.
An endocrinology panel rarely holds one kind of patient. A single day can include a person with type 1 diabetes on an insulin pump, another being monitored for a thyroid nodule, a patient on long-term glucocorticoids who needs a bone density scan, and someone being worked up for a pituitary or adrenal disorder. Each of those follows its own coverage rule, its own frequency limit, and often its own authorization pathway.
The revenue loss in this specialty rarely comes from the visit itself. It comes from small, code-specific rules stacking up: how often a glucose monitor reading can be billed, when a bone scan becomes payable again, how many education hours remain on a patient's benefit, and whether the right modifier was attached on a day a procedure and an office visit happened together. A2Z Billings tracks those rules at the claim level, so fewer of them turn into denials.
A short list of coding and coverage rules decides whether most endocrinology claims get paid without a fight. These are the areas we build checks around before a claim ever leaves the office.
The E08–E13 code families are combination codes. The "with" convention ties diabetes directly to a complication, so a note that stops at "diabetes" defaults to an unspecified code that payers routinely question.
Interpreting a continuous glucose monitor and billing for the data transmission are two different services with two different code sets. Mixing them, or reporting either one more than the calendar allows, is one of the most common denial triggers we see.
Under NCD 150.3, a bone mass measurement is payable once every 24 months, counted from at least 23 months after the last covered scan. Earlier testing is allowed with documented medical necessity, such as monitoring long-term glucocorticoid use.
An ultrasound-guided thyroid fine needle aspiration is reported per lesion, with imaging guidance bundled into the procedure code rather than billed on its own. The supporting note needs the lesion count and the guidance confirmation to match.
DSMT is billed under NCD 40.1 in 30-minute units, with up to 10 hours available in a patient's first 12 months and up to 2 hours a year after that. It requires an accredited program and a written referral on file before the first unit is billed.
GLP-1 therapy, growth hormone, insulin pumps, CGM devices, and osteoporosis injectables each move through their own review process, and the rules shift depending on whether the drug is prescribed for diabetes or for weight management.
The errors that cost an endocrinology practice money tend to be the same handful, over and over. These are the ones we catch before submission rather than after a denial letter arrives.
Endocrinology reimbursement leans on documentation that most other specialties do not need to track. Charge capture gaps usually start here, because the supporting detail lives across the note, the lab flowsheet, and the device report.
Prior authorization has become one of the heavier parts of endocrinology billing, largely because of the medications and devices the specialty prescribes.
GLP-1 therapy now runs on two separate tracks. When it is prescribed for type 2 diabetes, it moves through standard pharmacy benefit review. When it is prescribed for weight management, coverage depends on the plan and, for many Medicare patients, on a separate, temporary bridge authorization with its own body mass index thresholds and a fixed monthly copay, kept apart from the diabetes pathway entirely. Growth hormone therapy generally needs documented deficiency and stimulation testing before a payer will approve it. Insulin pumps and CGM devices are typically reviewed as durable medical equipment, with their own supplier and documentation rules.
Renewals need attention: A GLP-1 approval tied to weight-management coverage usually depends on documented clinical benefit, so a missed weight or lab entry at follow-up can stall a refill. Growth hormone renewals need continued documentation of response to treatment, and buy-and-bill injectables such as denosumab or zoledronic acid add the extra step of matching the drug lot to the claim. We track these by patient and by plan, and we appeal denials with the documentation each payer asks for.
An endocrinology revenue cycle holds up best when the front desk and the billing team are working from the same rules, so one missed authorization does not repeat across a month of claims.
Eligibility checks that confirm remaining DSMT hours, DXA timing, and whether a drug or device needs authorization before the visit is scheduled.
Monitoring services, education units, and injections are reconciled against the day's schedule so nothing recurring gets missed.
Claims are coded to the specificity the chart supports, with the correct modifiers, lesion counts, and current claim edits applied before submission.
Denials are worked back to their root cause, appealed with the supporting documentation, and receivables are followed through to payment.
We apply endocrinology's rules at the claim level rather than treating every service the same way. Coding follows current CPT and ICD-10-CM guidance alongside the coverage rules each payer applies.
Remaining DSMT hours, DXA timing, and device or drug authorization status are confirmed ahead of the appointment, not after the claim is denied.
Type, control status, and complications are captured across the full diabetes code family instead of defaulting to an unspecified code.
GLP-1, growth hormone, CGM devices, and injectables are prepared, submitted, and followed through renewal and appeal.
Correct FNA lesion counts and modifier use on same-day visits and procedures, checked before the claim goes out.
A recurring frequency or specificity issue is fixed once, at the pattern level, instead of being corrected one claim at a time.
Visibility into denial reasons, authorization turnaround, and days in accounts receivable, reviewed on a regular cadence.
95251, the analysis, interpretation, and report, requires at least 72 hours of monitoring data and is payable no more than once per calendar month. It is not billed together with a remote monitoring interpretation code for the same data set, and it does not require a face-to-face visit on its own.
The two most common reasons are timing and diagnosis. Under NCD 150.3, a bone mass measurement is covered once every 24 months, so a scan ordered before roughly 23 months have passed is denied unless a documented exception applies. The other frequent cause is a diagnosis code paired with 77080 that does not establish medical necessity on its own.
The note needs to name the diabetes type, the control status, and any complication or manifestation, so the combined code and any related long-term drug use code can be assigned correctly. A note that only says "diabetes" forces an unspecified code and weakens the claim.
Yes. When a GLP-1 is prescribed for type 2 diabetes, it moves through standard pharmacy review. When it's prescribed for weight management, many plans, including a current Medicare pathway, require a separate authorization with its own eligibility criteria and cost structure. We prepare and track both, and we work renewals and appeals as they come up.
DSMT is billed under NCD 40.1 with G0108 for individual sessions and G0109 for group sessions, in 30-minute units. A patient's first 12 months allow up to 10 hours, and each year after that allows up to 2 hours, through an accredited program with a written referral from the treating provider.
Yes, when the visit is significant and separately identifiable from the procedure. Modifier 25 is appended to the office visit code. For an ultrasound-guided FNA billed under 10005, the imaging guidance is not billed separately, since it is bundled into the procedure code.
If diabetes coding, CGM frequency rules, DXA timing, DSMT limits, or GLP-1 authorization are slowing your practice down, we can review your recent claims and denials and show you exactly where the revenue is going.
